drugset / Trial / NCT00331136

Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria

NCT00331136

Non-randomizedFactorialOpen-labelTreatment

Summary

The purpose of this study is to evaluate three dose levels of a combination tablet and a fixed dose granule formulation of pyronaridine and artesunate (PA) for the treatment of acute uncomplicated falciparum malaria in children.

Timeline

Start
2006-06
Primary completion
2006-12
Completion
2006-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 2 mg/kg Oral
Subject Artesunate Small molecule 3 mg/kg Oral
Subject Artesunate Small molecule 4 mg/kg Oral
Subject Pyronaridine Unknown 6 mg/kg Oral
Subject Pyronaridine Unknown 9 mg/kg Oral
Subject Pyronaridine Unknown 12 mg/kg Oral